No document available.
Keywords :
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology; Animals; Behavior, Animal/drug effects; Benzazepines/pharmacology; Bromocriptine/pharmacology; Defecation/drug effects; Dopamine Agents/pharmacology; Dopamine Antagonists; Imidazoles/pharmacology; Motor Activity/drug effects; Parasympatholytics/pharmacology; Rats; Rats, Inbred Strains
Abstract :
[en] It has been found that dopaminergic transmission could be involved in some aspects of anxiety. The present study aims to explore this hypothesis further, using specific DA1 (SKF 38393) and DA2 (bromocriptine) agonists or DA1 (SCH 23390), and DA2 (zetidoline) antagonists in the open-field test. The results confirm previous studies indicating that DA1 and DA2 agonists predominantly increase locomotor activity, while DA1 and DA2 antagonists predominantly decrease it. However, at low doses, the four drugs increase the peripheral ambulation score significantly and, with the exception of zetidoline, also increase the central ambulation score. The observations made with zetidoline confirm the hypothesis that a specific presynaptic DA2 antagonism could be determinant for the disinhibitory effects of low doses of neuroleptics. A collateral action on 5HT transmission is also suggested to explain an hypothetic anxiolytic action of DA agonists and SCH 23390 at lower doses.
Scopus citations®
without self-citations
26